VOR BIOPHARMA INCVOR
ASignal's systematic analysis rates VOR as Neutral.
Reflects the latest available analysis · analyzed Sep 19, 2026
The case on VOR
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong financial health score (0.9)
- High cash position with total cash of $466.13M
- Low total debt of $2.88M resulting in strong liquidity
- Current ratio of 19.15x indicating excellent short-term financial health
- Value score of 0.9 suggests deep value or significant undervaluation
- Negative MACD histogram indicating bearish momentum
- Price below SMA20 and EMA20 signaling short-term downtrend
- Negative price momentum (-0.146)
- Negative operating cash flow of $-140.09M
- Negative free cash flow of $-79.50M
- Negative profit, net, operating, and gross margins
See the full verdict on VOR
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes VOR
Most investors never get a second opinion, let alone several. ASignal runs VOR past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.